Ann: Annual Report to shareholders , page-6

it's a good problem watching one programme jump ahead of another (i know that was a few months back), but the once lead 'pain' programme is now in the middle of the pack.

Yet it is a programme with some massive commercial advantages should they get it some decent funding to clear any current obstructions and get it into the clinic.

Lest Prof Mallucci and her lab announce they've cracked the ddRNAi route to silencing PERK and are heading to the clinic for all the big CNS diseases. Two areas they've spent considerable time researching.